GlassScriptPhysician profile
Shaelyn Gibson
NPI 1982363412
$929.95
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $185 · 2023: $506 · 2024: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $164.55 | 2022-2023 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $163.97 | 2023-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $157.56 | 2023-2024 | Austedo Xr |
| Alkermes, INC. | $75.63 | 2023-2024 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $69.90 | 2022-2023 | Jornay Pm |
| Abbvie INC. | $67.22 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.86 | 2023 | |
| Axsome Therapeutics, INC. | $41.44 | 2023 | Auvelity |
| Lundbeck LLC | $40.32 | 2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $28.91 | 2023 | Qelbree |
| Bausch Health US, LLC | $20.52 | 2023 | Aplenzin |
| Janssen Pharmaceuticals, INC | $18.57 | 2023 | Spravato |
| Noven Therapeutics, LLC | $17.79 | 2023 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $17.71 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaelyn Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.